Prima Biomed in trading halt

By Tim Dean
Tuesday, 17 November, 2009

Cancer treatment specialist pharmceutical company, Prima Biomed (ASX:PRR), has requested a trading halt on its shares until November 19 pending an announcement regarding the development its oral vaccine for cervical cancer.

Prima Biomed's flagship product is CVac, which is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of ovarian cancer.

Prima Biomed has had a stellar year on the markets. It began the year around $0.005 and rose around 3,200% to its current price.

Prima Biomed shares were last trading at 16.5c.

Content from other channels on our network

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Nestlé launches on-pack date-labelling pilot to help tackle food waste

Handling the protein powder boom: engineering solutions for powder processing

Seafood safety researcher awarded at NZIFST Food Industry Awards

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

Energy crisis will have long‍-‍term effects: Australian Industry Group

Myriota launches hybrid 5G satellite and cellular IoT network

Funding program for smaller businesses to access additive manufacturing

Collaboration provides NZ's largest smart water meter upgrade

ARENA backs Sicona battery technology to boost EV performance

Prima Biomed in trading halt

Scientists search for cystitis pain 'off switch'

Australia's first cases of H5 avian influenza confirmed

AusBiotech partners with Tenmile

Content from other channels on our network